Edgestream Partners’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $9.25M | Buy |
+73,604
| New | +$9.25M | 0.26% | 91 |
|
|
2025
Q1 | – | Sell |
-12,574
| Closed | -$1.72M | – | 970 |
|
|
2024
Q4 | $1.72M | Buy |
12,574
+7,308
| +139% | +$998K | 0.07% | 432 |
|
|
2024
Q3 | $607K | Sell |
5,266
-38,928
| -88% | -$4.49M | 0.03% | 667 |
|
|
2024
Q2 | $6.08M | Buy |
44,194
+20,189
| +84% | +$2.78M | 0.29% | 76 |
|
|
2024
Q1 | $3.31M | Buy |
24,005
+10,002
| +71% | +$1.38M | 0.17% | 208 |
|
|
2023
Q4 | $1.85M | Buy |
14,003
+11,957
| +584% | +$1.58M | 0.13% | 265 |
|
|
2023
Q3 | $230K | Sell |
2,046
-10,657
| -84% | -$1.2M | 0.02% | 768 |
|
|
2023
Q2 | $1.2M | Sell |
12,703
-24,569
| -66% | -$2.32M | 0.11% | 316 |
|
|
2023
Q1 | $3.77M | Buy |
37,272
+19,118
| +105% | +$1.94M | 0.42% | 44 |
|
|
2022
Q4 | $2.17M | Buy |
18,154
+9,365
| +107% | +$1.12M | 0.24% | 136 |
|
|
2022
Q3 | $933K | Buy |
8,789
+3,620
| +70% | +$384K | 0.07% | 282 |
|
|
2022
Q2 | $504K | Sell |
5,169
-20,954
| -80% | -$2.04M | 0.04% | 407 |
|
|
2022
Q1 | $2.45M | Sell |
26,123
-19,933
| -43% | -$1.87M | 0.2% | 176 |
|
|
2021
Q4 | $3.92M | Buy |
+46,056
| New | +$3.92M | 0.24% | 129 |
|
|
2021
Q2 | – | Sell |
-8,857
| Closed | -$861K | – | 512 |
|
|
2021
Q1 | $861K | Buy |
+8,857
| New | +$861K | 0.05% | 305 |
|